You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR ULTRALENTE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ultralente

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00222521 ↗	Insulin Glargine Vs Standard Insulin Therapy	Completed	Moran, Antoinette, M.D.	Phase 3	2003-04-01	This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 ↗	Insulin Glargine Vs Standard Insulin Therapy	Completed	Sanofi	Phase 3	2003-04-01	This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 ↗	Insulin Glargine Vs Standard Insulin Therapy	Completed	University of Minnesota	Phase 3	2003-04-01	This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 ↗	Insulin Glargine Vs Standard Insulin Therapy	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 3	2003-04-01	This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Ultralente

Condition Name

Chart
Table

Condition Name for Ultralente
Intervention	Trials
Type 1 Diabetes	2
Cystic Fibrosis Related Diabetes	1
Diabetes Mellitus, Type 1	1
Diabetes Mellitus, Type 2	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Ultralente
Intervention	Trials
Diabetes Mellitus	4
Diabetes Mellitus, Type 1	3
Diabetes Mellitus, Type 2	2
Fibrosis	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Ultralente

Trials by Country

Map
Table

Trials by Country for Ultralente
Location	Trials
United States	42
Canada	14
India	7
Italy	7
Germany	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Ultralente
Location	Trials
Kentucky	3
California	3
Texas	3
Nebraska	3
Illinois	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Ultralente

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Ultralente
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Ultralente
Clinical Trial Phase	Trials
Completed	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ultralente

Sponsor Name

Chart
Table

Sponsor Name for Ultralente
Sponsor	Trials
Sanofi	2
Pfizer	2
Moran, Antoinette, M.D.	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Ultralente
Sponsor	Trials
Other	6
Industry	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.